Multiple myeloma with t(11;14): impact of novel agents on outcome

Puertas, Borja; González‐Calle, Verónica; Sobejano-Fuertes, Eduardo; Escalante, Fernando; Rey-Bua, Beatriz; Bueno, Irene; Puig, Noemí; Gutiérrez, Norma C.; Mateos, María-Victoria

doi:10.1038/s41408-023-00807-9

Cited by 7 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with clinical findings of our study, Puertas et al (17) showed that greater people in the t (11;14) group had oligosecretory illness (although not substantially more) and more people had non-secretory disease (10.5 vs. 1.6%) compared to the SR group, while fewer people in the t (11;14) group had the IgA subtype (12.6 vs. 24.7%) or the light-chain kappa (51.6 vs. 63.6%). Blood calcium levels were higher in the t(11;14) group (9.97 mg/dL 1.36 vs. 9.62 mg/dL 1.37), and there was a decreased incidence of plasmacytomas (both paraskeletal and extramedullary types) in the t(11;14) group (17.2 vs. 38.6 percent).…”

Section: Resultssupporting

confidence: 94%

“…Survival rates were considerably lower for patients with hypercalcemia and bone disease compared to people with anemia or renal failure. Puertas et al (17) found after a median follow-up of 80.1 months that 41.1% of patients were still living at the time of the last contact (range, 1.2-273.8 months).…”

Section: Resultsmentioning

confidence: 99%

“…In study performed by Puertas et al (17) failure to achieve complete remission (CR) after induction and 2 microglobulin levels below 5.0 mg/dL. Patients were followed for a median of 80.1 months (range: 1.2-273.8 months), and 239 of them/ (41%) were still alive at the time of the last contact.…”

Section: Resultsmentioning

confidence: 99%

“…Puertas et al (17) t(11;14) revealed a trend toward a better response when novel agents were used in first line. Those given novel agents (87.2%) were not significantly different from those given traditional agents (79.5%).…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Impact of CRAB Criteria on The Prognosis of Patients with Multiple Myeloma Compared to Other Prognostic Factors in The Era of Novel Agents

Yousef,

El-Zorkany,

Metwally

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Multiple myeloma can be distinguished from asymptomatic myeloma and monoclonal gammopathy of uncertain significance thanks to CRAB factors. Objective: To assess role of CRAB factors in prognosis of cases who had multiple myeloma and being treated with novel therapeutic agents in comparison with non-novel agents. Patients and Methods: A comparative cross-sectional study was conducted in the Hematology Unit, Internal Medicine Department, in Zagazig University Hospitals on 100 patients with multiple myeloma. We looked at how the existence of CRAB factors affected the survival rates of individuals with symptomatic myeloma who were receiving novel therapies. Results: Hb, PLT, albumin were higher in Novel Containing Regimen (NCR) group than Non-Novel Containing Regimen (NNCR) group, while creatinine, Bence Jones protein in urine, serum beta-2-microglobulin and calcium were lower in (NCR) group than (NNCR) group. Bone marrow plasma cells after treatment, lytic lesion, anemia, hypercalcemia and renal insufficiency were lower in (NCR) group than (NNCR) group. About 91% of patients had M protein type IGG and 9% had IGA, the mean bone marrow plasma cells was 24.6 ± 4.3, 21% had abnormal cytogenetics, 25% had high risk FISH, 70% had lytic lesions, 17% had EMD at diagnosis, 29% had anemia (decrease of Hb more than 2 g/dl or to equal or less than 10 g/dl), 17% had hypercalcemia ≥11.5 mg/dl, 16% had renal insufficiency (increase of serum creatinine more than 2 g/dl). Conclusion: Overall survival and progression-free survival for myeloma patients treated with new medicines; both significantly improved.

show abstract

Section: Resultssupporting

confidence: 94%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Impact of CRAB Criteria on The Prognosis of Patients with Multiple Myeloma Compared to Other Prognostic Factors in The Era of Novel Agents

Yousef,

El-Zorkany,

Metwally

2023

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…While direct comparison across trials is not feasible, it is evident that RRMM with high-risk cytogenetics does respond to POM + LD-Dex treatment. Thus, POM + LD-Dex appears to be efficacious for Chinese RRMM patients with high-risk cytogenetics and remains a favorable option for general RRMM patients, irrespective of high-risk cytogenetics [ 21 , 22 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial

Zhou,

Wang,

Chen

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

This multicenter, open-label, single-arm trial (ClinicalTrials.gov, NCT05236621) was conducted to confirm the efficacy and safety of generic pomalidomide plus dexamethasone in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Total 79 eligible RRMM patients were planned to be included. Patients were treated with generic pomalidomide (4 mg daily on days 1–21, orally) and low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally; 20 mg for patients aged > 75 years) in 28-day cycles until disease progression with a maximum treatment duration of 2 years. The primary endpoint is the overall response rate (ORR) assessed by the independent review committee per the 2016 International Myeloma Working Group guidelines. A total of 85 eligible patients were included in this study from 32 centers in China, with a median age of 62.0 (range, 39–76) years, a median prior line of therapy of 4 (range, 1–16), and 41.2% patients with high-risk cytogenetics. The ORR was 38.8% (95% confidence interval (CI), 28.44–50.01). The disease control rate was 67.1% (95% CI, 56.02–76.87), meanwhile, the median progression-free survival was 5.55 months (95% CI, 3.68–7.52). Among the treatment-related adverse events (TRAEs), infective pneumonia (17.6%) was the most frequent non-hematologic adverse event, while a decrease in neutrophil count (52.9%) was the most common grade ≥ 3 TRAE. The study results indicated that the generic pomalidomide demonstrated consistent efficacy and a safety profile similar to the branded pomalidomide when combined with low-dose dexamethasone in Chinese RRMM patients.Registration number ClinicalTrials.gov NCT05236621, retrospectively registered on February 11, 2022.

show abstract

T(11;14) with multiple myeloma: Standard risk survival but slow and poor response

Liu,

Xu,

Yan

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Multiple myeloma with t(11;14): impact of novel agents on outcome

Cited by 7 publications

References 46 publications

Impact of CRAB Criteria on The Prognosis of Patients with Multiple Myeloma Compared to Other Prognostic Factors in The Era of Novel Agents

Impact of CRAB Criteria on The Prognosis of Patients with Multiple Myeloma Compared to Other Prognostic Factors in The Era of Novel Agents

Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial

T(11;14) with multiple myeloma: Standard risk survival but slow and poor response

Contact Info

Product

Resources

About